The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjects with persistent depressive disorder VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Health Canada has approved a phase 2 clinical trial…

Source

Previous articlePsychedelic Drug Policy Reform in 2021
Next articlePT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest – Judaism, Christianity, and Embracing Psychedelics